| Document |
Document Title |
|
WO/2022/169284A1 |
The present invention relates to a novel compound which enables additional hydrogen bonding with amino acids at specific positions of histone acetyltransferase (HAT) p300 through the structural analysis of HAT p300. The novel compound ac...
|
|
WO/2022/157106A1 |
The presently claimed invention relates to a process for the preparation of mono-, di-, tri-, fluoro arylamide or hetroarylamide.
|
|
WO/2022/152705A1 |
Compounds of Formula (I) wherein R1, R3, R11, R12, X, Y1, Y2, Y3, Y4 and formula (II) are as defined in the description. Medicaments.
|
|
WO/2022/152109A2 |
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nuc...
|
|
WO/2022/149462A1 |
A light-absorbing material according to one embodiment of the present disclosure includes a compound represented by formula (1) as a main component. In formula (1): R1 to R30 are independent of each other and include at least one element...
|
|
WO/2022/150314A1 |
The present disclosure is concerned with substituted phenyl and heterocycloalkyl compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical canc...
|
|
WO/2022/145923A1 |
The present invention relates to a pharmaceutical composition which is for preventing or treating viral infections and contains a piperlongumine-based compound as an active ingredient. Specifically, the piperlongumine-based compound acco...
|
|
WO/2022/145707A1 |
The present invention provides a novel piperlongumine-based compound, and an immunomodulator and a health functional food for immunomodulation, which comprise the compound or a pharmaceutically acceptable salt or solvate thereof as an ac...
|
|
WO/2022/133594A1 |
The present disclosure relates to methods for the hydroaminoalkylation of an olefin. Such methods can comprise reacting the olefin with a secondary amine in the presence of a catalyst of Formula (I). The present disclosure also relates t...
|
|
WO/2022/133544A1 |
Cannabidiol (CBD) cannabinoids and CBD cannabinoid analogues with, inter alia, antimicrobial activity, synthetic methods for the preparation thereof and medical uses and formulations containing same.
|
|
WO/2022/134287A1 |
The present invention relates to a method for preparing a carboxylic acid ester compound. Under the catalysis of nitrite, an carboxylic acid reacts with an alcohol in air so as to obtain an ester compound; and the alcohol is ethanol, pro...
|
|
WO/2022/140654A1 |
The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts thereof.
|
|
WO/2022/134297A1 |
The present invention relates to a preparation method for a carboxylate ester compound, comprising: under the catalysis of a nitrite ester, reacting carboxylic acid and methanol in air, so as to obtain an ester compound. The preparation ...
|
|
WO/2022/132455A1 |
A composition comprises one or more trimesic acid derivatives of Formula (I) in which R1, R2, and R3 are independently selected from the group consisting of alkyl groups. A polymer composition comprises a composition as described above a...
|
|
WO/2022/133236A1 |
Forms of 2-(4-chlorophenoxy)-N-[3-[5-[cis-3-(trifluoromethoxy)cyclobu
tyl]-1,3,4-oxadiazol-2-yl]-1-bicyclo[1.1.1]pentanyl]acetamid
e, designated herein as Compound I, were prepared and characterized in the solid state. Also provided are ...
|
|
WO/2022/121317A1 |
Disclosed is a 1,1'-biphenyl-2,6-diphenolic compound and the use thereof. The 1,1'-biphenyl-2,6-diphenolic compound is a new compound, and has good biological activity. By means of in vitro tumor cell activity experiments, it was found t...
|
|
WO/2022/120048A1 |
The present disclosure is directed to chromane compounds, chromane compounds demonstrating HDAC inhibition, and pharmaceutical compositions thereof. Additional embodiments include methods of using the chromane compounds. For example, the...
|
|
WO/2022/112347A1 |
The present invention relates to malonamide compounds of the formula (I) wherein the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of sai...
|
|
WO/2022/111493A1 |
A use of a complex of an ARB metabolite and an NEP inhibitor in the preparation of drugs for the prevention and/or treatment of nephropathy.
|
|
WO/2022/102557A1 |
The present invention relates to: a compound represented by formula (I) (in the formula, X denotes -CH2- or -NH-; R1 and R3 each independently denote a substituted or unsubstituted hydrocarbon group having 5-30 carbon atoms, with any -CH...
|
|
WO/2022/103838A1 |
The present disclosure relates to methods of screening compounds which reduce or inhibit CHMP7 in neuronal cells or a population of cells and methods of inhibiting CHMP7 expression in a cell to treat one or more subjects suffering from o...
|
|
WO/2022/104137A1 |
The disclosure provides recording materials including propane derivatized monomers and polymers for use in volume Bragg gratings, including, but not limited to, volume Bragg gratings for holography applications. Several structures are di...
|
|
WO/2022/100487A1 |
Disclosed is an amino-combretastatin derivative, and in particular a compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of the pharmaceutically acceptable salt thereof...
|
|
WO/2022/104383A1 |
Provided are compounds useful for treating, preventing, reducing the occurrence of, slowing the progression of, or reducing, ameliorating, or alleviating the symptoms associated with a condition selected from the group consisting of: pre...
|
|
WO/2022/091065A1 |
In a cocrystal, a pharmaceutical composition comprising same, and a preparation method therefor, of the present invention, a novel cocrystal comprises niclosamide and nafamostat, or a pharmaceutically acceptable salt thereof. The novel c...
|
|
WO/2022/092260A1 |
The present invention addresses the problem of providing a cross-coupling reaction method that can use a wide variety of compounds as starting materials, that can substantially not use organic solvent, and that can rapidly provide reacti...
|
|
WO/2022/088302A1 |
The present invention relates to the technical field of organic synthesis of tire rubber, in particular, to a preparation method for isophthalamide. The isophthalamide is prepared by using m-phthalodinitrile as a reaction raw material, a...
|
|
WO/2022/084046A1 |
The present invention relates to a process for preparing methyl methacrylate (MMA) and/or methacrylic acid (MAS) with improved yield, comprising the process steps of amidation, conversion and hydrolysis/esterification, especially high yi...
|
|
WO/2022/082752A1 |
A DMF recycling method. The method comprises: a neutralization step: adding an alkaline neutralizer into a DMF stock solution, controlling the pH value of the mixed solution to be within a preset range, and carrying out a neutralization ...
|
|
WO/2022/083494A1 |
The present application relates to a cis-para-substituted cyclohexylaminonitrile salt represented by formula (I), a preparation method therefor and use thereof as an intermediate for preparing a pesticide, and a method for preparing the ...
|
|
WO/2022/079574A1 |
The present disclosure provides compositions and methods for reducing inflammation to improve or maintain mental health or physical health in an individual. In some aspects, the compositions include at least one 5HT2A agonist and at leas...
|
|
WO/2022/075396A1 |
[Problem] The purpose of the present invention is to provide a compound which is suitable for a low refractive index layer in a capping layer in order to improve the light extraction efficiency of an organic EL element. [Solution] The pr...
|
|
WO/2022/072401A1 |
Provided herein are small molecule inhibitors of coronavirus attachment and entry, related pharmaceutical compositions, uses, and methods thereof, wherein the compound has a structure of Formula (I):
|
|
WO/2022/071363A1 |
Provided is a new production method for a fluorinated organic compound (1) which involves a step A in which, in a liquid composition containing an organic solvent, IF5 is used to fluorinate a hydrogen atom-containing organic compound (2)...
|
|
WO/2022/073003A1 |
The present application provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, R1, R2, R3 and R4 are described herein. The methods of using these compounds to inhibit tetramerization of PF4 and to tr...
|
|
WO/2022/063350A1 |
The subject of the present invention is a lipidoid of general formula (I), wherein X, Y, Z and R are as defined in the claims. This lipidoid is useful as a transfection agent. The invention further describes transfection agents, transfec...
|
|
WO/2022/064454A1 |
The present invention discloses a process for the synthesis of compound of formula (VII) or a salt thereof, wherein, R, R1, R2, R3, R4a and R4b are as defined in the detailed description. The process further comprises the synthesis of an...
|
|
WO/2022/053541A1 |
The present invention relates to new compounds having appetite-suppressing effects and their uses as a drug for treating diseases and disorders, especially metabolite syndrome.
|
|
WO/2022/053804A1 |
The present invention relates to a composite form of tetraacetylethylenediamine (TAED) and a method for its preparation. The composite form may comprise a new crystalline form. The invention also relates to the crystalline form itself. T...
|
|
WO/2022/053784A1 |
There is described a crystalline Form III of tetraacetylethylenediamine (TAED). Form III has a powder X-ray diffraction pattern measured using Cu (Kα) radiation containing a reflective peak at a 2θ value corresponding to the following ...
|
|
WO/2022/048922A1 |
The present invention relates to a compound of the following formula (I) or (II), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture the...
|
|
WO/2022/040782A1 |
The present invention provides a method for preventing and/or slowing progression of and/or treating pulmonary fibrosis comprising administration of a therapeutically effective amount of fenretinide, fenretinide analog or pharmaceuticall...
|
|
WO/2022/043435A1 |
The present invention relates to a compound which can be used in the treatment of infections caused by SARS coronaviruses, e.g. by blocking the active site of the proteases 3CLpro and PLpro. The compound can be used as inhibitor or label...
|
|
WO/2020/249956A9 |
Compounds of general formula (I), which are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A. wherein A is defined as Formula.
|
|
WO/2022/041462A1 |
A synthesis method for a cyclopropane compound. The cyclopropane compound has a structure as represented by general formula (I). The synthesis method comprises: reacting an olefin compound A with ethyl diazoacetate under the catalysis of...
|
|
WO/2022/037465A1 |
The present invention relates to a lipid nanoparticle. The lipid nanoparticle is formed by a compound of the following structure (I) or pharmaceutically acceptable salt, tautomer or stereisomer thereof. The present invention also provide...
|
|
WO/2022/040180A1 |
The present invention is related to processes for preparing ruxolitinib, or a salt thereof, and related synthetic intermediates related thereto.
|
|
WO/2022/037512A1 |
Disclosed is the use of a complex of an angiotensin II receptor antagonist metabolite and an NEP inhibitor in the treatment of heart failure, specifically relating to the use of the complex in the preparation of a drug for treating heart...
|
|
WO/2022/035804A1 |
The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof and pharmaceutical composition comprising the compound of formula (I). The present composition also relates to methods treating a d...
|
|
WO/2022/026657A1 |
Compositions that include cationic surfactants and methods of synthesizing compositions that include cationic surfactants. The surfactants include a quaternary amine and a saturated or unsaturated alkyl chain with 4 to 28 carbons. The su...
|
